After experiencing dejection and criticism, a breath of relief seems to have surfaced for Bharat Biotech as the World Health Organisation is likely to grant approval for the indigenously developed Covid vaccine, Covaxin in its Emergency Use Listing (EUL), this week, Dr. NK Arora, Chairman, COVID working group said.
Currently, Covaxin is among the three main anti-Covid vaccines that are been administered in India. The indigenously developed Covaxin is manufactured by Hyderabad-based Bharat Biotech and has been in news over non-disclosure of the three stages trial report before it was approved for emergency use in India by DCGI.
Emergency approval of Covaxin by WHO will allow Bharat Biotech to export its vaccines and also ease international travel stringencies. The assessment is performed by the product evaluation group, composed of regulatory experts from around the world and a Technical Advisory Group. So far, WHO has approved seven vaccines and enlisted in its EUL.
Last month Bharat Biotech said that it was exploring opportunities with its international partners who have expertise in manufacturing commercial-scale inactive viral vaccines. The trail reports of Covaxin have claimed that it has 77. 8 percent efficacy rate and is highly effective in fighting against symptomatic coronavirus.
Covaxin is exclusively a ‘Made in India’, vaccine, developed under joint efforts by Bharat Biotech, ICMR, and the National Institute of Virology. The vaccine is derived from an inactive cell as they do not replicate and has a less pathological effect. Covaxin is established using vaccine adjuvants that are added to the vaccine for boosting immunogenicity.